In a new study, an experimental obesity drug from Novo Nordisk, CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company's stock price to fall by as much as 29%. Yes, fall. For anyone not following the heated race for obesity drug dominance, it may look like we're living upside-down. After all, if this data were unveiled three years ago, the market reaction would have been wildly different. The stock might have gone up and headlines would have heralded an advance in the fight against obesity. But we're in a new era of obesity medicine. The bar for success, once modest, has soared—especially so for CagriSema. Let me explain.
Though Novo will make mind-blowing money from its existing obesity drugs in the coming years (its GLP-1 drugs are likely to become pharma's most lucrative franchise next year), CagriSema was seen as essential for continued growth in 2030 and beyond. And the study suggests it may not be the contender investors had hoped for.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
A boycott of Costco for its DEI efforts is not likely to succeed
The US retailer has a loyal base of shoppers that it's unlikely to lose
Wealth tax: Let's judge it by principles of taxation
Tax canons laid down by Adam Smith remain relevant, though his list has been extended. Test the idea of a wealth tax against these, lest we get carried away by progressive idealism
MFD, RIA, RA: Explore your career as a financial adviser
Understand the earning potential, licensing and compliance to choose your best suited path
Hacked in 2024? India's privacy rules require you to take action
Draft digital personal data protection rules demand that data breaches be reported retrospectively
Cutting Through the Clutter: Key Focus Areas for Retail Investors in 2025
Remember that social media is for fun, and not serious topics such as personal finance advice
Health insurance claims: How to ensure grievance redressal
My health insurer recently rejected my claim, citing my inability to provide key internal hospital papers that they require.
Assam mining tragedy: Rescue operations on for fourth day
Rescue operations by multiple state and central agencies continued for the fourth day on Thursday to locate trapped miners inside an illegal rat-hole coal mine in Dima Hasao district of Assam, officials said.
Bank officers' union warns of strike
Bank officers' union AIBOC on Thursday threatened to go on a nationwide strike on 24-25 February to press for their various demands, including a five-day work week and adequate recruitment in all cadres.
Centre to give LPG subsidy to oil PSUs
The government is likely to provide a subsidy of ₹35,000 crore to state-owned Indian Oil Corporation Ltd (IOC), Bharat Petroleum Corporation Ltd (BPCL), and Hindustan Petroleum Corporation Ltd (HPCL) to make up for losses they incurred on selling the fuel this fiscal, people aware about the development said.
Earthquake-hit Tibet calls off search
Chinese officials say the focus is shifting to relocating the displaced survivors.
